Jump to Main Content

FDA Alerts

FDA Approves Voxelotor for Sickle Cell Disease

The Food and Drug Administration granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics) for adults and pediatric patients 12 years of age and older with sickle cell disease.
Citations